10-K: Penumbra to be Acquired by Boston Scientific for $14.5B

Penumbra, a leading thrombectomy company, announced its acquisition by Boston Scientific for approximately $14.5 billion, following a year of strong revenue and operational income growth.

Summary

• Penumbra will be acquired by Boston Scientific Corporation for approximately $14.5 billion, with stockholders having the right to elect to receive $374 per share in cash or 3.8721 shares of Boston Scientific common stock, subject to proration (approximately 73% cash and 27% stock).
• The merger is expected to close by the end of 2026, subject to customary closing conditions, including stockholder and regulatory approvals.
• Revenue for the year ended December 31, 2025, increased by 17.5% to $1,403.7 million, up from $1,194.6 million in 2024.
• Income from operations significantly improved to $189.2 million in 2025 (13.5% of revenue) from $9.3 million in 2024, which was impacted by a $115.3 million charge related to exiting the immersive healthcare business.
• Net income for 2025 was $177.7 million, a substantial increase from $14.0 million in 2024.
• Gross margin increased to 67.1% in 2025 from 63.2% in 2024, with the 2024 margin impacted by a $33.4 million inventory write-down.
• Thrombectomy product revenue grew by 16.2% to $947.9 million in 2025, and Embolization and Access product revenue grew by 20.2% to $455.7 million.
• The company completed enrollment for its THUNDER Study (neurovascular CAVT technology) in September 2024.
• Penumbra is expanding its manufacturing capabilities with new facilities in Costa Rica, expected to be completed in 2026.
• A share repurchase program authorized up to $200.0 million, with $100.4 million repurchased in Q3 2024, and the remaining $100.0 million authorization extended to December 31, 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as highly positive due to the premium acquisition offer from Boston Scientific, reflecting strong confidence in Penumbra's market position and innovative product portfolio, alongside robust financial performance in 2025.

Positives

• Significant revenue growth of 17.5% in 2025, reaching $1,403.7 million.
• Substantial improvement in income from operations to $189.2 million in 2025, compared to $9.3 million in 2024.
• Net income saw a strong rebound to $177.7 million in 2025 from $14.0 million in 2024.
• Gross margin improved to 67.1% in 2025, indicating better cost management and product mix.
• Strong growth in both key product categories: Thrombectomy revenue up 16.2% and Embolization and Access revenue up 20.2%.
• Completion of enrollment for the THUNDER Study, a key clinical trial for neurovascular applications.
• Strategic expansion of manufacturing with new facilities in Costa Rica.
• The proposed acquisition by Boston Scientific Corporation at an enterprise value of $14.5 billion, offering stockholders $374 per share, represents a significant premium.
• Effective internal control over financial reporting maintained as of December 31, 2025.

Negatives

• The 2024 financial results were significantly impacted by a strategic decision to exit the immersive healthcare business, incurring $115.3 million in impairment and other charges.
• International revenue growth (6.6%) lagged behind U.S. revenue growth (21.0%) in 2025.
• The company's stock performance (177.66 on a $100 investment from 2020-2025) underperformed the NYSE Composite (151.49) but outperformed the S&P Healthcare Equipment Index (77.66) over the same period, indicating mixed market perception prior to the merger announcement.
• The share repurchase program is subject to Boston Scientific's approval under the Merger Agreement, limiting future independent capital allocation.
• The company has never paid cash dividends and does not anticipate doing so in the foreseeable future.

Risks

• Uncertainty associated with the agreement to be acquired by Boston Scientific Corporation could adversely affect business, including employee retention, customer relationships, and supplier dealings.
• Failure to complete the Merger could lead to a decline in stock price, negative publicity, and a $525.0 million termination fee payable to Boston Scientific.
• Substantial transaction-related costs will continue to be incurred in connection with the Merger.
• The company and its directors/officers may be subject to lawsuits relating to the Merger, potentially delaying or preventing its completion.
• Provisions of the Merger Agreement may deter alternative business combinations and could negatively impact the stock price if the Merger Agreement is terminated in certain circumstances.
• The market price of Boston Scientific Corporation common stock may fluctuate, making the market value of the stock consideration uncertain for Penumbra stockholders.
• Existing products may be rendered obsolete, and the company may be unable to effectively introduce and market new products or keep pace with technological advances.
• Significant competition from large, well-capitalized companies could hinder market penetration or improve results of operations.
• Inability to achieve or maintain satisfactory pricing and margins for products due to price competition or increased costs.
• Future growth depends on further penetrating the current customer base, increasing product use frequency, and expanding the user base to additional specialist physicians and healthcare providers in both existing and future target end markets.
• Lack of resources to successfully market and sell products could adversely affect business and results of operations.
• Third-party reimbursement may not be available or adequate for procedures using products, and may be subject to change.
• Dependence on a limited number of product families means a decline in sales of any of these could adversely affect revenue and business prospects.
• If specialist physicians or other healthcare providers do not recommend, endorse, or use products, or if relationships deteriorate, market acceptance could be adversely affected.
• Dependence on key suppliers puts the company at risk of interruptions in product availability.
• Uncertainty about manufacturing products in high volumes at commercially reasonable costs.
• Requirement to maintain high levels of inventory consumes working capital and could lead to write-downs or write-offs.
• Defects or failures associated with products could lead to recalls, safety alerts, product-related or securities litigation, significant costs, and negative publicity.
• Clinical trials conducted by the company, competitors, or third parties may yield unfavorable results, adversely affecting business.
• Stringent domestic and foreign medical device regulations may impede approval/clearance, hinder development/manufacturing, or result in recalls/seizures.
• Subject to federal, state, and foreign healthcare laws and regulations (e.g., Anti-Kickback Statute, False Claims Act, Sunshine Act, FCPA) that could result in significant liability.
• Inability to maintain or protect intellectual property rights (patents, trademarks, trade secrets) could harm business.
• Potential involvement in lawsuits to protect/enforce intellectual property or defend against infringement accusations, which could be expensive and time-consuming.
• Changes in patent law could diminish the value of patents.
• Non-compliance with governmental patent agency requirements could reduce or eliminate patent protection.
• Inadequate protection of trademarks and trade names could harm name recognition.
• Inability to protect the confidentiality of trade secrets and other proprietary information could harm competitive position.
• Need for additional financing in the future, which may not be available on favorable terms or at all, potentially delaying/reducing R&D.
• Acquisitions and business development arrangements incur costs and risks (integration, unanticipated liabilities, diversion of management, loss of key employees).
• Fluctuations in effective tax rate and changes to tax laws may adversely affect the company.
• The price of common stock may be volatile, and stockholders could lose all or part of their investment.
• Executive officers, directors, and largest stockholders (36.2% aggregate voting stock) may significantly influence management and operations, potentially not aligning with other stockholders' interests.
• A sale of a substantial number of shares could cause the market price to drop significantly.
• Techniques employed by short sellers may drive down the market price of common stock.
• Corporate governance provisions (e.g., blank check preferred stock, no written consent, restrictions on calling special meetings, and a staggered board transitioning to non-staggered) could discourage acquisitions or prevent stockholder attempts to replace management.
• Designation of Delaware courts as exclusive forum for certain disputes could limit stockholders' ability to access a favorable judicial forum.
• No anticipation of paying cash dividends; stockholders must rely on stock appreciation.
• An additional valuation allowance against deferred tax assets could require a charge to earnings.
• No guarantee of additional share repurchases under the program.
• Difficulty in forecasting future performance, leading to unpredictable financial results.
• Exposure to the risk of nonpayment by customers.
• Natural disasters and other events beyond control (earthquakes, wildfires, pandemics, geopolitical instability) could harm business.
• Failure to protect information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could disrupt operations.
• Operations subject to environmental, health and safety, and data privacy laws and regulations, compliance with which may be costly.
• Significant costs and management time incurred as a public company.
• Failure to maintain an effective system of disclosure controls and procedures and internal control over financial reporting could impair ability to produce timely and accurate financial statements.
• Inaccurate or unfavorable research by securities/industry analysts or cessation of coverage could cause stock price/trading volume to decline.

Future Outlook

The company expects to continue developing and building its portfolio of thrombectomy, embolization, and access technologies, iterating on currently available products. The merger with Boston Scientific Corporation is anticipated to close by the end of 2026, subject to customary closing conditions. The company plans to continue investments in product development and expand its salesforce, while also preparing for potential increases in personnel and inventory ahead of new product launches. The global regulatory environment is expected to continue evolving, potentially increasing the time, cost, and complexity of obtaining regulatory approvals. The company intends to grow its business internationally, which will require substantial spending to expand direct sales or attract additional distributors. No cash dividends are anticipated in the foreseeable future.

Management Comments

• "Penumbra, the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia."
• "We believe that the cost-effectiveness of our products is attractive to our customers."
• "We attribute our success to our culture built on cooperation, our highly efficient product innovation process, our disciplined approach to product and commercial development, our deep understanding of our target end markets and our relationships with specialist physicians and other healthcare providers."
• "We believe these factors have enabled us to rapidly innovate in a highly efficient manner."
• "We believe we have adequate supplies or sources of availability of raw materials necessary to meet our needs."
• "We believe our employee relations are good."
• "We believe our current sources of liquidity will be sufficient to meet our liquidity requirements for at least the next 12 months."

Industry Context

StockSavvy.ai notes that Penumbra's strong performance in thrombectomy and embolization/access markets aligns with the growing demand for minimally invasive endovascular procedures. The acquisition by Boston Scientific, a major player in the medical device industry, highlights the strategic value of Penumbra's innovative technologies and market leadership in thrombectomy, particularly given the intense competition from other large, well-capitalized companies like Medtronic and Stryker. The industry is characterized by rapid technological advancements and a focus on improved clinical outcomes and cost-effectiveness, areas where Penumbra has demonstrated success.

Comparison to Industry Standards

• Penumbra's 17.5% revenue growth in 2025 and 20.2% growth in embolization and access products demonstrate strong market penetration and product acceptance, potentially outpacing some competitors in specific high-growth segments of the medical device market.
• The gross margin of 67.1% in 2025 is competitive within the specialized medical device sector, especially considering the R&D investments.
• The enterprise value of $14.5 billion in the acquisition by Boston Scientific suggests a premium valuation for Penumbra's specialized portfolio and market position, reflecting confidence in its future growth potential compared to general industry multiples.
• The company's focus on computer-assisted vacuum thrombectomy (CAVT) for conditions like ischemic stroke and pulmonary embolism positions it at the forefront of innovation, potentially setting new benchmarks for speed, safety, and simplicity in clot removal procedures, which could differentiate it from broader offerings by diversified competitors like Medtronic or Terumo.

Corporate Governance

Legal Proceedings

• Putative class action and Private Attorney General Act (PAGA) representative action lawsuits were filed in April 2023 by a former contractor and a current employee, respectively, in California Superior Court, alleging various claims under the California Labor Code related to wages, overtime, meal and rest breaks, and business expenses.
• The claims were settled for an aggregate amount of $4.6 million in May 2024, with court approval granted in March 2025.
• Substantially all payments under the settlement agreement were completed by June 30, 2025, and final court approval was granted in February 2026.
• The company was involved in a securities class action lawsuit in 2021, which was voluntarily dismissed without prejudice.

Stakeholder Impact

• Shareholders: Will receive $374 per share in cash or Boston Scientific stock upon merger completion, representing a significant premium. Existing shareholders will experience dilution if they elect stock consideration.
• Employees: May experience uncertainty about their roles following the merger; the company aims to attract and retain key talent. The company emphasizes competitive compensation, professional development, and a healthy work environment.
• Customers: May experience uncertainty regarding possible changes to products, technology, or policies post-merger. The company's continued product innovation and expansion aim to drive improved clinical and health outcomes.
• Suppliers/Vendors/Business Partners: May experience uncertainty regarding current or future business relationships with the company post-merger.
• Regulatory Authorities: The merger is subject to regulatory approvals, and the company continues to operate under stringent domestic and foreign medical device regulations.

Next Steps

• Complete the merger with Boston Scientific Corporation by the end of 2026, subject to stockholder and regulatory approvals.
• Continue to develop and build the portfolio of thrombectomy, embolization, and access technologies.
• Iterate on currently available products.
• Expand manufacturing operations, including the construction of a new facility and warehouse in Costa Rica, expected to be completed in 2026.
• Continue to make investments in product development.
• Increase the salesforce.
• Monitor and evaluate the full impact of the One Big Beautiful Bill Act (OBBBA) legislative changes as additional supplemental guidance becomes available.
• Evaluate and defend against any lawsuits relating to the Merger.
• Potentially repurchase remaining $100.0 million of common stock under the share repurchase authorization, subject to Boston Scientific's approval.

Key Dates

Recommendation

The proposed acquisition by Boston Scientific at a substantial premium of $374 per share, representing an enterprise value of approximately $14.5 billion, provides a clear and attractive exit for shareholders. This, combined with Penumbra's strong financial performance in 2025, including significant revenue growth and a rebound in profitability, and its leading position in the high-growth thrombectomy market, makes the stock a strong buy for investors seeking to capitalize on the merger arbitrage opportunity or the underlying value recognized by the acquirer.

Keywords

Thrombectomy, Embolization, Medical Devices, Ischemic Stroke, Pulmonary Embolism, Acute Limb Ischemia, Vascular Disease, Neurovascular, Boston Scientific Acquisition, SEC Filing, Healthcare Technology, Interventional Radiology, Neurosurgery, Cardiology